Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apotransferrin dose-escalation study in congenital atransferrinemia
2024-515986-33-00Phase 2Authorised
- Sponsor
- Prothya Biosolutions
- Start
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of apotransferrin in Atransferrinemia, sponsored by Prothya Biosolutions. Primary endpoints: Increase of hemoglobin to normal range, Pharmacokinetics of transferrin and 1 more. Planned start Nov 2010; status: authorised.
02
Drugs
apotransferrin
03
Conditions
Atransferrinemia
Beyond the preview
Go deeper on 2024-515986-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515986-33-00.